Becton, Dickinson and Company $BDX Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 23.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,429 shares of the medical instruments supplier’s stock after selling 4,347 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Becton, Dickinson and Company were worth $2,805,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Activest Wealth Management lifted its holdings in shares of Becton, Dickinson and Company by 285.3% in the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 97 shares during the period. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at $25,000. Steph & Co. raised its position in shares of Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 65 shares during the period. WPG Advisers LLC raised its position in shares of Becton, Dickinson and Company by 64.2% during the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 61 shares during the period. Finally, Accredited Wealth Management LLC raised its position in shares of Becton, Dickinson and Company by 77.8% during the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 70 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the topic of a number of recent analyst reports. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research report on Tuesday, April 14th. Evercore boosted their target price on Becton, Dickinson and Company from $180.00 to $190.00 in a research report on Thursday, May 7th. Weiss Ratings lowered Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. JPMorgan Chase & Co. cut their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 10th. Finally, Jefferies Financial Group cut their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $184.86.

Becton, Dickinson and Company Stock Up 0.1%

NYSE:BDX opened at $147.76 on Monday. The firm has a market capitalization of $40.71 billion, a price-to-earnings ratio of 37.41, a PEG ratio of 10.45 and a beta of 0.22. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The business’s fifty day moving average price is $152.83 and its 200 day moving average price is $178.08.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.Becton, Dickinson and Company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, sell-side analysts forecast that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase plan on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.